Physician profile
Rena Fortier
NPI 1396730610
$8,267.98
in general payments reported to CMS, 2019-2025
28 companies · $943 in 2025
The $943 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $616 · 2021: $1,125 · 2022: $1,548 · 2023: $1,385 · 2024: $1,679 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,646 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.44 |
| Education | $359.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,004.05 | 2019-2025 | Tremfya |
| Genzyme Corporation | $863.16 | 2019-2025 | |
| Merz North America, INC. | $695.46 | 2022-2025 | |
| Abbvie INC. | $609.79 | 2020-2025 | |
| Galderma Laboratories, L.P. | $566.42 | 2019-2024 | Aklief |
| Regeneron Healthcare Solutions, INC. | $539.86 | 2020-2025 | Dupixent |
| Allergan, INC. | $532.24 | 2021-2022 | |
| Pfizer INC. | $471.12 | 2019-2025 | |
| Incyte Corporation | $453.72 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $402.50 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $370.99 | 2019-2024 | Winlevi, Absorica Ld |
| Amgen INC. | $313.64 | 2019-2024 | Otezla, Enbrel |
| Ucb, INC. | $248.70 | 2021-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $202.04 | 2019-2023 | |
| Leo Pharma INC. | $184.59 | 2021-2025 | Adbry, Anzupgo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $140.71 | 2019-2025 | Cabtreo |
| Lilly USA, LLC | $124.93 | 2022-2024 | Olumiant, Taltz, Ebglyss |
| Almirall LLC | $113.68 | 2019-2024 | Klisyri |
| Epi Health, LLC | $93.09 | 2019-2021 | |
| Sebela Pharmaceuticals INC. | $87.11 | 2019-2023 | Pramosone, Naftin |
| E.R. Squibb & Sons, L.L.C. | $76.67 | 2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $47.75 | 2023-2024 | Zoryve |
| Journey Medical Corporation | $33.97 | 2020-2021 | |
| Prugen, INC. Pharmaceuticals | $33.26 | 2019 | |
| Sandoz INC. | $20.86 | 2020 | |
| Merck Sharp & Dohme LLC | $17.61 | 2019 | |
| Nabriva Therapeutics, Plc | $11.81 | 2020 | |
| Organon LLC | $8.25 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Fortier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.